GlassScriptPhysician profile
Laura Gleaton
NPI 1134986151
$794.77
in general payments reported to CMS, 2019-2025
22 companies · $501 in 2025
The $501 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $294 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $97.27 | 2024 | Ojjaara |
| Astrazeneca Pharmaceuticals LP | $73.42 | 2025 | Enhertu, Lynparza, Calquence |
| Eisai INC. | $73.04 | 2024-2025 | |
| Genmab U.S., INC. | $69.98 | 2025 | Tivdak, Epkinly |
| Janssen Biotech, INC. | $61.04 | 2025 | Rybrevant, Tecvayli, Darzalex |
| Sobi, INC | $51.39 | 2024-2025 | |
| Daiichi Sankyo INC. | $46.96 | 2025 | Enhertu, Vanflyta |
| Emd Serono, INC. | $43.43 | 2025 | |
| Genentech USA, INC. | $27.87 | 2024 | Phesgo, Perjeta, Itovebi |
| Geron Corporation | $25.75 | 2024 | Rytelo |
| Novartis Pharmaceuticals Corporation | $25.13 | 2025 | |
| Aveo Pharmaceuticals, INC. | $25.12 | 2025 | |
| Merck Sharp & Dohme LLC | $21.46 | 2024 | Keytruda |
| Takeda Pharmaceuticals U.S.A., INC. | $20.98 | 2024 | Alunbrig |
| Exelixis INC. | $20.62 | 2025 | Cabometyx |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $17.50 | 2025 | Xtandi |
| Beone Medicines USA, INC. | $17.22 | 2025 | Brukinsa |
| Springworks Therapeutics, INC. | $16.92 | 2025 | Ogsiveo |
| Beigene USA, INC. | $15.75 | 2024 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $15.61 | 2024 | Monoferric |
| Blueprint Medicines Corporation | $14.29 | 2025 | Ayvakit |
| Karyopharm Therapeutics INC. | $14.02 | 2025 | Xpovio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Gleaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.